losartan has been researched along with Acute Myelogenous Leukemia in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mansour, RSH | 1 |
| Al Khawaja, AY | 1 |
| Hamdan, II | 1 |
| Khalil, EA | 1 |
1 other study available for losartan and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
IR microspectroscopic investigation of the interaction of some losartan salts with human stratum corneum protein and its effect on losartan transdermal permeation.
Topics: Amlodipine; Humans; Keratins; Leukemia, Myeloid, Acute; Losartan; Pharmaceutical Preparations; Salts | 2023 |